Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: Long-term results of a phase II trial

Oncology (Switzerland)

Volumn 84, Issue 6, 2013, Pages 342-349

  Iwase, Hiroaki ^a   Shimada, Masaaki ^a   Tsuzuki, Tomoyuki ^a   Hirashima, Noboru ^a   Okeya, Masayuki ^a   Hibino, Yusuke ^a   Ryuge, Nobumitsu ^a   Yokoi, Misaki ^a   Kida, Yuichi ^a   Kuno, Takeshi ^a   Tanaka, Yusaku ^a   Kato, Bunichiro ^a   Esaki, Masaya ^a   Urata, Noboru ^a   Kato, Eriko ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Chemoradiotherapy; Cisplatin; Complete response; Esophageal cancer; Fluoropyrimidine; S 1

Indexed keywords

CISPLATIN; CREATININE; FLUOROPYRIMIDINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ESOPHAGUS CANCER; ESOPHSIDE EFFECTAGUS PAIN; FATIGUE; FEBRILE BONE MARROW APLASIA; FEMALE; HUMAN; HYPERPIGMENTATION; LOCALLY ADVANCED ESOPHAGEAL CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; ORAL MUCOSITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84877858399     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000348383     Document Type: Article

References (28)

1. Mariette C, Piessen G, Triboulet JP: Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007; 8: 545-553.
2. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U: Histological tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1, 000 consecutive resections at a single center in the Western world. Ann Surg 2001; 234: 360-369.
3. Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-1598.
4. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623-1627.
5. Crosby TD, Brewster AE, Borley A, Perschky L, Kehagioglou P, Court J, Maughan TS: Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 2004; 90: 70-75.
6. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, Satake M, Ishikura S, Ogino T, Miyata Y, Seki S, Kaneko K, Nakamura A: Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17: 2915-2921.
7. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-557.
8. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A, Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10: 1063-1069.
9. Harada K, Kawaguchi S, Supriatno, Kawashima Y, Yoshida H, Sato M: S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB. Cancer Lett 2005; 226: 161-168.
10. Iwase H: Radiotherapy combined with S-1 and cisplatin for locally advanced and metastatic esophageal cancer (in Japanese). Gan To Kagaku Ryoho 2006; 33(suppl 1):224-229.
11. Sobin LH, Wittekind C: International Union against Cancer (UICC) TNM Classification of Malignant Tumors, ed 5. New York, Wiley-Liss, 1997, pp 54-88.
12. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W: Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000; 47: 13-47.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
14. Japanese Society for Esophageal Diseases: Guidelines for Clinical and Pathologic Studies on Carcinoma of the Esophagus, ed 9. Tokyo, Kanehara, 2001.
15. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174.
16. Button MR, Morgan CA, Croydon ES, Roberts SA, Crosby TD: Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009; 73: 818-823.
17. Ilson DH, Bains M, Kelsen DP, O'Reilly E, Karpeh M, Coit D, Rusch V, Gonen M, Wilson K, Minsky BD: Phase I trial of escalatingdose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol 2003; 21: 2926-2932.
18. Brenner B, Ilson DH, Minsky BD, Bains MS, Tong W, Gonen M, Kelsen DP: Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 2004; 22: 45-52.
19. Li QQ, Liu MZ, Hu YH, Liu H, He ZY, Lin HX: Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus 2010; 23: 253-259.
20. Conroy T, Yataghene Y, Etienne PL, Michel P, Senellart H, Raoul JL, Mineur L, Rives M, Mirabel X, Lamezec B, Rio E, Le Prise E, Peiffert D, Adenis A: Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. Br J Cancer 2010; 103: 1349-1355.
21. Iwase H, Morise K: Chemotherapy combined with radiation for advanced esophageal carcinoma. Intern Med 1992; 31: 1433-1434.
22. Iwase H, Shimada M, Nakamura M, Nakarai K, Iyo T, Kaida S, Indo T, Kato E, Horiuchi Y, Kusugami K: Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: long-term results of a phase II study of UFT/CDDP with radiotherapy. Int J Clin Oncol 2003; 8: 305-311.
23. Tahara M, Ohtsu A, Hironaka S, Boku N, Ishikura S, Miyata Y, Ogino T, Yoshida S: Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 2005; 35: 316-323.
24. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-2317.
25. Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Hara T, Denda T, Tawada K, Imagumbai T, Araki H, Sakai M, Hatano K, Kawakami H, Uno T, Ito H, Yokosuka O: Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2011; 80: 119-125.
26. Ohyanagi F, Yamamoto N, Horiike A, Harada H, Kozuka T, Murakami H, Gomi K, Takahashi T, Morota M, Nishimura T, Endo M, Nakamura Y, Tsuya A, Horai T, Nishio M: Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced nonsmall-cell lung cancer. Br J Cancer 2009; 101: 225-231.
27. Maruyama R, Hirai F, Ondo K, Kometani T, Hamatake M, Seto T, Sugio K, Ichinose Y: Concurrent chemoradiotherapy using cisplatin plus S-1, an oral fluoropyrimidine, followed by surgery for selected patients with stage III non-small cell lung cancer: a singlecenter feasibility study. Surg Today 2011; 41: 1492-1497.
28. Tahara M, Minami H, Kawashima M, Kawada K, Mukai H, Sakuraba M, Matsuura K, Ogino T, Hayashi R, Ohtsu A: Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck. Cancer Sci 2011; 102: 419-424.